Iterion Therapeutics
PrivateLast Round
Grant
Feb 16, 2022
Total Funding Raised
$41.91M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Iterion Therapeutics is a clinical-stage biopharmaceutical company that develops novel targeted cancer therapeutics, including its lead product tegavivint, a first-in-class small molecule inhibitor of TBL1.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iterion Therapeutics Comparables
Compare Iterion Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sapience Therapeutics | 85% | |
| Redx Pharma Plc | 82% | |
| StemSynergy Therapeutics, Inc. | 81% |
Iterion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 16, 2022 | ||||
| Series B | Feb 16, 2021 | ||||
| Series B | Dec 5, 2018 | ||||
| Grant | Feb 19, 2014 |
Iterion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GOOSE Capital | Series B |
| GPG Ventures | Series B |
| Viva BioInnovator | Series B |
| Venture Investors LLC | Series B |
| Lumira Ventures | Series B |
| Cancer Prevention and Research Institute of Texas | Grant |
| AngelMD | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 37% MoM, from 917 to 1.3K.
- Feb 16, 2022
Received $3M from the Cancer Prevention and Research Institute of Texas.
Recent news
Latest coverage and updates
- hiresAug 12, 2026
Iterion Therapeutics hired Bob as independent directors on Aug 12th '26.
- receives_financingAug 12, 2026
Iterion Therapeutics receives financing of $26M.
- hiresAug 12, 2026
Iterion Therapeutics hired Manuel Aivado as Independent Board Members on Aug 12th '26.
- hiresAug 12, 2026
Iterion Therapeutics hired Bob Smith as Independent Board Members on Aug 12th '26.
Iterion Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Iterion Therapeutics's valuation, stock price, and market status.
Is Iterion Therapeutics a public or private company?
Iterion Therapeutics is a private company.
What is the current stock price of Iterion Therapeutics?
Iterion Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Iterion Therapeutics worth (valuation)?
Valuation information for Iterion Therapeutics is not publicly available.
Can I buy Iterion Therapeutics stock?
Iterion Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Iterion Therapeutics's last funding round?
Iterion Therapeutics's most recent funding round was Grant on February 16, 2022.
Who are the main investors in Iterion Therapeutics?
Key investors in Iterion Therapeutics include Lumira Ventures.
Will Iterion Therapeutics IPO soon?
No public IPO plans have been announced for Iterion Therapeutics.
How can I track Iterion Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Iterion Therapeutics's secondary market activity and sign up for updates.